← Evidence map

ArticleFrontiers in oncology2026

HER2-targeted PET-imaging with [68Ga]Ga-ABY-025 to predict targeted-therapy response in HER2-expressing metastatic breast cancer: study protocol of a multicenter, prospective, open-label trial.

Renske Altena et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

The trial

NCT0683038270 enrolled2025

HER2-targeted PET-imaging with [68Ga]Ga-ABY-025 to predict targeted-therapy response in HER2-expressing metastatic breast cancer: study protocol of a multicenter, prospective, open-label trial. | OpenQuestion